S-1: Longeveron Files for Resale of 3.56 Million Shares Following Warrant Inducement

Longeveron is registering the resale of up to 3,563,764 shares of its Class A common stock by selling stockholders after a recent warrant inducement transaction.

Summary

• Longeveron has filed a registration statement for the resale of up to 3,563,764 shares of its Class A common stock.
• These shares are issuable upon the exercise of warrants held by certain selling stockholders.
• The warrants were issued as part of a June 2024 warrant inducement transaction.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders unless the warrants are exercised.
• If all warrants are exercised for cash, Longeveron could receive up to approximately $9.0 million.
• Longeveron intends to use any proceeds from the exercise of the June private placement warrants for its ongoing clinical and regulatory development of Lomecel-B for the treatment of several disease states and indications, including HLHS and Alzheimers Disease, obtaining regulatory approvals; capital expenditures, working capital and other general corporate purposes.
• The company is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs.
• Their lead investigational product is Lomecel-B, an allogeneic Medicinal Signaling Cells (MSC) formulation sourced from the bone marrow of young, healthy adult donors.
• Longeveron is currently focusing on three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimers disease (AD) and Aging-related Frailty.
• The company is currently conducting a Phase 2b trial (ELPIS II) to compare the effects of Lomecel-B as an adjunct therapeutic versus standard-of-care (HLHS surgery alone).
• In September 2023, Longeveron completed their Phase 2a AD clinical trial, known as the CLEAR MIND trial, which demonstrated positive results.
• The company has discontinued its clinical trial in Japan to evaluate Lomecel-B for Aging-related Frailty.
• The company will continue to enroll patients on the Aging-related Frailty and Cognitive Impairment registry trials in The Bahamas and plans to also launch an Osteoarthritis registry trial in the Bahamas.
• Longeveron operates a current good manufacturing practice (cGMP)-compliant manufacturing facility and produce their own product candidates for testing.
• On March 26, 2024, Longeveron effected a 1-for-10 reverse stock split.
• On April 8, 2024, Longeveron commenced a public offering of Class A common stock and pre-funded warrants.
• On April 16, 2024, the Company entered into an inducement letter agreements (the Inducement Letter Agreements) with certain holders of its existing October private placement warrants, and certain April common stock warrants to purchase up to an aggregate of 1,914,894 shares of Class A common stock.
• On June 17, 2024, the Company entered into inducement letter agreements (collectively, the June Inducement Letter Agreements) with holders of its existing Series D warrants to purchase 1,697,891 shares of the Companys Class A common stock.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it highlights the potential for a capital raise and ongoing clinical trials, it also acknowledges the company's history of losses and need for additional funding. The positive sentiment stems from the potential of Lomecel-B and the ongoing clinical development.

Positives

• Longeveron has the potential to receive $9.0 million if all warrants are exercised.
• The company has ongoing clinical trials for Lomecel-B in HLHS and Alzheimer's disease.
• The CLEAR MIND trial for Alzheimer's showed positive results.
• Longeveron operates a cGMP-compliant manufacturing facility.
• The company is actively pursuing strategic collaborations for the advancement of Lomecel-B in addressing AD.

Negatives

• The company will not receive any proceeds from the resale of shares by selling stockholders unless the warrants are exercised.
• Longeveron has discontinued its clinical trial in Japan to evaluate Lomecel-B for Aging-related Frailty.
• The company has a history of losses and may need to raise additional capital to continue as a going concern.

Risks

• The company may not receive the full $9.0 million if not all warrants are exercised.
• Clinical trials may not be successful.
• The company may face difficulties in raising additional capital.
• The market price of the company's Class A common stock may be volatile.
• The company's dual-class structure may adversely affect the trading market for its Class A common stock.
• The company's cash resources are insufficient to fund its planned operations or development plans beyond the second quarter of 2025.

Future Outlook

Longeveron expects that the net proceeds from recent offerings, together with its existing cash, will be sufficient to fund its operations into the second quarter of 2025. The company plans to continue the research and development of Lomecel-B and explore strategic collaborations.

Industry Context

Longeveron operates in the regenerative medicine and biotechnology industry, which is focused on developing innovative therapies for unmet medical needs. The company's focus on cell-based therapies and its pipeline of product candidates targeting HLHS, Alzheimer's disease, and aging-related frailty align with broader industry trends in these areas.

Comparison to Industry Standards

• Longeveron's approach to using allogeneic Medicinal Signaling Cells (MSCs) for regenerative medicine places it among companies like Mesoblast and Athersys, which are also developing MSC-based therapies.
• The focus on Hypoplastic Left Heart Syndrome (HLHS) is relatively unique, as few companies are specifically targeting this rare congenital heart defect, setting Longeveron apart from broader cardiovascular therapeutic developers like Amgen or Novartis.
• In the Alzheimer's disease space, Longeveron's CLEAR MIND trial results put them in competition with companies like Biogen and Eli Lilly, which have approved or are developing therapies targeting amyloid plaques, though Longeveron's approach with Lomecel-B focuses on different mechanisms such as immunomodulation and tissue repair.
• For aging-related frailty, Longeveron's work aligns with companies exploring senolytics and other interventions to improve healthspan, such as Unity Biotechnology and BioAge Labs, though Longeveron's specific cell therapy approach offers a distinct modality.

Stakeholder Impact

• Shareholders may experience dilution if additional shares are issued.
• Employees' jobs are dependent on the company's ability to secure funding and advance its product candidates.
• Patients with HLHS and Alzheimer's disease could benefit from successful development of Lomecel-B.
• Suppliers and creditors are dependent on the company's financial stability.

Next Steps

• The selling stockholders may offer and sell the Class A common stock from time to time.
• Longeveron will continue to pursue clinical development of Lomecel-B for HLHS and Alzheimer's disease.
• The company will continue to analyze the data in order to further develop our clinical development strategy.
• The company will continue to enroll patients on the Aging-related Frailty and Cognitive Impairment registry trials in The Bahamas and plans to also launch an Osteoarthritis registry trial in the Bahamas.
• Longeveron will be opportunistic and consider entering into co-development, out-licensing, or other collaboration agreements for the purpose of eventually commercializing Lomecel-B and other products domestically and internationally if appropriate approvals are obtained.
• The company will continue to expand our intellectual property portfolio.

Key Dates

Keywords

Longeveron, Lomecel-B, Class A Common Stock, Warrants, Resale, HLHS, Alzheimer's Disease, Clinical Trials, Reverse Stock Split, Warrant Inducement